TGTX Q3 2025 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$162M+92.8% YoY

Gross Profit

$134M82.6% margin

Operating Income

$29M18.2% margin

Net Income

$391M241.7% margin

EPS (Diluted)

$2.43

QoQ Revenue Growth

+14.6%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$418M

Stockholders' Equity

$607M

Cash & Equivalents

$74M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$162M	$84M	+92.8%
Gross Profit	$134M	$75M	+79.2%
Operating Income	$29M	$12M	+136.2%
Net Income	$391M	$4M	+9974.6%

Revenue Segments

Product

$159M99%

License Revenue

$2M1%

Geographic Segments

UNITED STATES

$153M100%